Hr-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Hr-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck sq…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases [Phase 2]
A Phase 2 clinical trial evaluating brain radiotherapy combined with dalpiciclib and endocrine therapy for HR-positive/HER2-negative advance…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer [Phase 3]
Phase 3 study evaluating RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant for locally advanced or metastatic PIK3CA-mutant HR+/HER2- bre…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer [Phase 2]
This document reports that the Phase 2 trial of QL1706 for neoadjuvant treatment of HR+/HER2- breast cancer is currently recruiting.
-
CLINICAL_TRIALS withdrawal · 2025-11-28Clinical Trial Update: A Real-World Study in Patients With HR+/HER2- Advanced Breast Cancer
A real-world study in HR+/HER2- advanced/metastatic breast cancer was withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
Real-world clinical trial update on sacituzumab govitecan as monotherapy or in combination for recurrent or metastatic HER2-negative breast …
-
CLINICAL_TRIALS trial_result · 2025-05-30Clinical Trial Update: Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC [Phase 2]
A Phase 2 clinical trial update reports results for sacituzumab govitecan with or without pembrolizumab in HR-positive, HER2-negative metast…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer [Phase 2]
This clinical trial update indicates a Phase 2 neoadjuvant study of Darsilide combined with an aromatase inhibitor, trastuzumab, and Patuzum…
-
CLINICAL_TRIALS research · 2024-11-26Clinical Trial Update: Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. [Phase 2]
A Phase 2 study evaluating radiotherapy followed by chemotherapy in combination with toripalimab for locally advanced HR-positive, HER2-nega…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy [NA]
This completed clinical trial evaluated patient-reported outcomes and physical activity in Japanese patients with HR+/HER2- advanced breast …
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer [Phase 3]
Phase 3 clinical trial evaluating a PARP inhibitor with a CDK4/6 inhibitor and endocrine therapy for HR+/HER2-negative metastatic breast can…
-
CLINICAL_TRIALS trial_result · 2024-08-14Clinical Trial Update: A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer [Phase 2]
Phase 2 study of ZW25 (zanidatamab) with palbociclib and fulvestrant in HER2+/HR+ advanced breast cancer completed; results have been posted…
-
CLINICAL_TRIALS trial_result · 2023-11-15Clinical Trial Update: Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial. [Phase 2]
A Phase 2 trial evaluating dalpiciclib in combination with fulvestrant and compound gossyfol acetate tablets for women with HR-positive, HER…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer [Phase 2]
Phase 2 clinical trial updating tucidinostat in combination with nab-paclitaxel for advanced HR+/HER2- breast cancer.
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer [Phase 2]
A Phase 2 clinical trial evaluating HS-10342 in Chinese patients with HR+/HER2- advanced and/or metastatic breast cancer is in the study pha…
-
FDA approval · 2021-09-15FDA Approved: KISQALI — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Kisqali (ribociclib) from Novartis Pharmaceuticals Corporation, expanding its labeling for u…
-
CLINICAL_TRIALS research · 2018-06-18Clinical Trial Update: A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer [Phase 2]
Phase 2 biomarker study evaluating the combination of palbociclib and fulvestrant in second- or third-line HR+/HER2-negative advanced breast…